Browse our 650+ Publications​

Latest Publications

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 | Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 | Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 | María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 | John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 | Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 | Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17 1 Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada 3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 4 University Medical Center Hamburg‐Eppendorf, Hamburg, Germany 5 Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany 6 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 7 Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA 8 Hospital Universitario Quirónsalud Madrid, Madrid, Spain 9 Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA 10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain 11Merck & Co., Inc, Rahway, New Jersey, USA 12GlaxoSmithKline, Upper Providence, Pennsylvania, USA 13GlaxoSmithKline, Waltham, Massachusetts, USA 14GlaxoSmithKline, Stevenage, UK 15GlaxoSmithKline, Durham, North Carolina, USA 16GlaxoSmithKline, Philadelphia, Pennsylvania, USA 17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1 , Clayton Jackson2 , Parveen Shiraz3 , Nikeshan Jeyakumar1 , Mark Hamilton1 , Emily Egeler4 , Sharon Mavroukakis4 , Adam Kuo4 , Juancarlos Cancilla4 , Bita Sahaf4 , Neha Agarwal3 , Alyssa Kanegai3 , Anne Marijn Kramer3,4 , Sally Arai3 , Sushma Bharadwaj3 , Saurabh Dahiya3 , Hitomi Hosoya3 , Laura Johnston3 , Vanessa Kennedy3 , Michaela Liedtke1 , Robert Lowsky3 , Lekha Mikkilineni3 , Robert Negrin3 , Andrew Rezvani3 , Surbhi Sidana3 , Judith Shizuru3 , Melody Smith3 , Wen-Kai Weng3 , Steven Feldman4 , Matthew J. Frank3,4 , Zachary Lee5 , Mary Tagliaferri5 , A. Mario Marcondes5 , David Miklos3,4 , Crystal Mackall4 , Lori Muffly3,4 Division of Hematology/Oncology, UT Southwestern, Dallas, TX; 3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4 Center for Cancer Cell Therapy, Stanford University, Stanford, CA; 5 Nektar Therapeutics, San Francisco, CA

Molecular disease monitoring in patients with relapsed/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy

Colton M, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2024
Authors and Affiliates
Colton, Meryl MD MSc1; Purev, Enkhtsetseg MD1; Haverkos, Bradley MD MPH1; Bair, Steven MD1; Jasem, Jagar MD MPH1; Allison Jacob MS2; Kamdar, Manali MD1 1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO 2. Adaptive Biotechnologies, Seattle WA

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Melani C, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
C. Melani, R. Lakhotia, S. Pittaluga, J.D. Phelan, D.W. Huang, G. Wright, J. Simard, J. Muppidi, C.J. Thomas, M. Ceribelli, F.A. Tosto, Y. Yang, W. Xu, T. Davies‑Hill, S.D. Pack, C.J. Peer, O. Arisa, E. Mena, L. Lindenberg, E. Bergvall, C.A. Portell, R.J. Farah, S.T. Lee, A. Pradhan, C. Morrison, A. Tadese, A.M. Juanitez, C. Lu, A. Jacob, H. Simmons, W.D. Figg, S.M. Steinberg, E.S. Jaffe, M. Roschewski, L.M. Staudt, and W.H. Wilson Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) — all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.)

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Bumma N, et al.
Journal of Clinical Oncology
June 2024
Authors and Affiliates
Naresh Bumma, MD1; Joshua Richter, MD2 ; Sundar Jagannath, MD2 ; Hans C. Lee, MD3 ; James E. Hoffman, MD4; Attaya Suvannasankha, MD5 ; Jeffrey A. Zonder, MD6 ; Mansi R. Shah, MD7 ; Suzanne Lentzsch, MD, PhD8 ; Rachid Baz, MD9 ; Joseph J. Maly, MD10; Swathi Namburi, MD11; Matthew J. Pianko, MD12 ; Jing Christine Ye, MD, MS12; Ka Lung Wu, MD, PhD13 ; Rebecca Silbermann, MD14 ; Chang-Ki Min, MD15; Marie-Christiane Vekemans, MD16; Markus Munder, MD17 ; Ja Min Byun, MD18 ; Joaqu´ın Mart´ınez-Lopez, MD19 ; Kaniel Cassady, PhD20 ; Michelle DeVeaux, PhD20; Dhruti Chokshi, BS20; Anita Boyapati, PhD20; Anasuya Hazra, PhD20; George D. Yancopoulos, MD, PhD20; L. Andres Sirulnik, MD, PhD20; Karen Rodriguez Lorenc, MD20; Glenn S. Kroog, MD20 ; Yariv Houvras, MD, PhD20; and Madhav V. Dhodapkar, MD21 1The Ohio State University Comprehensive Cancer Center, Columbus, OH 2Icahn School of Medicine at Mount Sinai, New York, NY 3The University of Texas MD Anderson Cancer Centre, Houston, TX 4University of Miami Health System, Miami, FL 5Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN 6Karmanos Cancer Institute, Detroit, MI 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 8Columbia University Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Swedish Cancer Institute, Seattle, WA 12Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Department of Hematology, Cliniques Universitaires Saint-Luc, Universit´e Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea 19Hospital 12 de Octubre, i112, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc, Tarrytown, NY 21Emory University School of Medicine, Atlanta, GA

Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab inRelapsed/Refractory CLL: Phase 1b BRUIN Trial

Roeker L, et al.
Blood
June 2024
Authors and Affiliates
Lindsey E. Roeker1, Jennifer A. Woyach2, Chan Y. Cheah3, Catherine C. Coombs4, Nirav N. Shah5, William G. Wierda6, Manish R. Patel7, Nicole Lamanna8, Donald E. Tsai9, Binoj Nair9, Chunxiao Wang10, Xiang Zhao9, Dan Liu10, David Radtke10, Sonya Chapman10, Narasimha Marella9, Samuel C. McNeely9, Jennifer R. Brown11 1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 3Linear Clinical Research, and Sir Charles Gairdner Hospital, and the University of Western Australia, Perth, Australia 4University of California, Irvine, Orange, CA, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6MD Anderson Cancer Center, Houston, TX, USA 7Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA 8Columbia University Medical Center/New York-Presbyterian, New York, NY, USA 9Loxo@Lilly, Indianapolis, IN, USA 10Eli Lilly and Company, Indianapolis, IN, USA 11Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Facon T, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Thierry Facon, M.D., Meletios‑Athanasios Dimopoulos, M.D., Xavier P. Leleu, M.D., Meral Beksac, M.D., Ludek Pour, M.D., Roman Hájek, M.D., Zhuogang Liu, M.D., Jiri Minarik, M.D., Philippe Moreau, M.D., Joanna Romejko‑Jarosinska, M.D., Ivan Spicka, M.D., Vladimir I. Vorobyev, M.D., Britta Besemer, M.D., Tadao Ishida, M.D., Wojciech Janowski, M.D., Sevgi Kalayoglu‑Besisik, M.D., Gurdeep Parmar, M.D., Pawel Robak, M.D., Elena Zamagni, M.D., Hartmut Goldschmidt, M.D., Thomas G. Martin, M.D., Salomon Manier, M.D., Mohamad Mohty, M.D., Corina Oprea, M.D., Marie‑France Brégeault, M.D., Sandrine Macé, Ph.D., Christelle Berthou, M.S., David Bregman, M.D., Zandra Klippel, M.D., and Robert Z. Orlowski, M.D., for the IMROZ Study Group Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the Department of Hemato-Oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava, Ostrava (R.H.), the Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc (J.M.), and the Charles University and General Hospital in Prague, Prague (I.S.) — all in the Czech Republic; Shengjing Hospital of China Medical University, Shenyang, China (Z.L.); the Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw (J.R.-J.), and the Department of General Hematology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, Łódź (P.R.) — both in Poland; the S.P. Botkin Moscow City Clinical Hospital, Moscow (V.I.V.); the Department of Hematology, Oncology, Immunology, and Rheumatology, University Hospital of Tübingen, Tübingen (B.B.), and the Department of Internal Medicine V, University of Heidelberg, Heidelberg (H.G.) — both in Germany; the Japanese Red Cross Medical Center, Tokyo (T.I.); Calvary Mater Newcastle, Newcastle, NSW (W.J.), and the Illawarra Cancer Care Centre, Wollongong, NSW (G.P.) — both in Australia; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy (E.Z.); the Division of Hematology–Oncology, University of California, San Francisco, San Francisco (T.G.M.); Sanofi, Patient Safety and Pharmacovigilance, Bridgewater, NJ (D.B.); Sanofi, Cambridge, MA (Z.K.); and the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.).

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu X, et al.
Nature Medicine
June 2024
Authors and Affiliates
Xavier Leleu 1,54 , Cyrille Hulin2,54, Jerome Lambert3, Arthur Bobin1, Aurore Perrot 4, Lionel Karlin5, Murielle Roussel6, Lydia Montes7, Brieuc Cherel8, Thomas Chalopin9, Borhane Slama10, Marie-Lorraine Chretien11, Kamel Laribi12, Claire Dingremont13, Christophe Roul14, Clara Mariette15, Sophie Rigaudeau16, Claire Calmettes17, Mamoun Dib18, Mourad Tiab19, Laure Vincent20, Jacques Delaunay21, Alberto Santagostino22, Margaret Macro23, Emmanuelle Bourgeois24, Frederique Orsini-Piocelle25, Julie Gay26, Benoit Bareau27, Noemie Bigot3, François Vergez28, Pierre Lebreton29, Reza Tabrizi30, Agathe Waultier-Rascalou31, Laurent Frenzel32, Ronan Le Calloch33, Emilie Chalayer34, Thorsten Braun35, Florence Lachenal36, Selim Corm37, Celine Kennel38, Rakiba Belkhir39, Jean-Sebastien Bladé40, Bertrand Joly41, Valentine Richez-Olivier42, Helene Gardeney1, Helene Demarquette43, Daniela Robu-Cretu44, Laurent Garderet45, Muriel Newinger-Porte46, Amine Kasmi47, Bruno Royer48, Olivier Decaux49, Bertrand Arnulf48, Karim Belhadj50, Cyrille Touzeau51, Mohamad Mohty52, Salomon Manier53, Philippe Moreau51, Hervé Avet-Loiseau28, Jill Corre 28 & Thierry Facon53 1Hematology, CIC 1082, U1313, CHU, University, Poitiers, France. 2CHU, Bordeaux, France. 3SBIM, Saint-Louis Hospital, Paris, France. 4University Hospital, iUCT Oncopole, Toulouse, France. 5Hôpital Lyon Sud, Pierre-Benite, France. 6Hematology, CHU, Limoges, France. 7Hematology, CHU, Amiens, France. 8CH Bretagne Atlantique, Vannes, France. 9Hematology, CHU, Tours, France. 10Hospital center, Avignon, France. 11Hematology, University Hospital, Inserm U1231, University of Burgundy Franche-Comté, Dijon, France. 12Hematology, CH, Le Mans, France. 13Internal Medicine, Tarbes-Lourdes Hospital, Tarbes, France. 14CH La Rochelle, La Rochelle, France. 15Hematology, CHU, Grenoble, France. 16Hématologie – Le Chesnay, CH Versaille, Paris, France. 17CH, Périgueux, France. 18University Hospital, Angers, France. 19Hematology, CH Departemental de La Roche-sur-Yon, La Roche-sur-Yon, France. 20CHU, Montpellier, France. 21Hôpital privé du confluent 2, Nantes, France. 22Hematology, CH, Troyes, France. 23Hematology, IHBN – CHU, Caen, France. 24GHICL, Lille, France. 25Hématologie, CH, Annecy Genevois, France. 26Hematology, CH de la côte basque, Bayonne, France. 27Hematology, Les Hôpitaux Privés Rennais Cesson Sévigné - Vivalto Santé, Cesson Sévigné, France. 28Unit for Genomics in Myeloma, iUCT Oncopole, Toulouse, France. 29Hematology, CH, Le Havre, France. 30Hematology, CHI de Mont De Marsan, Mont-de-Marsan, France. 31Hematology, CHU, Nîmes, France. 32Hematology, Necker Hospital, Paris, France. 33Hematology, CH de Cornouaille, Quimper Concarneau, Concarneau, France. 34Hematology, CHU, Saint-Etienne, France. 35Hematology, Avicenne hospital APHP, Bobigny, France. 36CH Pierre Oudot, Bourgoin-Jallieu, France. 37Medipole de Savoie, Challes les Eaux, France. 38CH William Morey, Chalon sur Saône, France. 39Rheumatology, Hopital Bicetre, AP-HP, Universite Paris Saclay, Paris, France. 40Onco-Hematology Department, HIA Sainte Anne, Toulon, France. 41CH Sud Francilien, Corbeil Essonnes, France. 42CHU de Nice, Nice, France. 43Hematology, CH, Dunkerque, France. 44Hematology, CH, Lens, France. 45Hopital Pitié Salpetriere, hématologie APHP, Paris, France. 46Hôpital Emile Muller, Mulhouse, France. 47DRC, CHU, Poitiers, France. 48Hôpital Saint-Louis, Paris, France. 49Hematology, UMR U1236, University Hospital, Rennes, France. 50C.H.U. Henri Mondor, Créteil, France. 51Hématologie, CHU Hotel Dieu Université, Nantes, France. 52Hematology, Sorbonne University, Saint-Antoine Hôpital (AP-HP), UMRs 938, Paris, France. 53Hematology, University Hospital Inserm U-S1277 and CNRS UMR9020, Lille, France. 54These authors contributed equally: Xavier Leleu, Cyrille Hulin.
Previous Next